This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): E7820
Description: E7820 is an orally administered aromatic sulfonamide derivative. It is a novel angiogenesis inhibitor that inhibits both proliferation and tube formation of human umbilical vein endothelial cell (HUVEC) induced by either basic fibroblast growth factor (bFGF) or VEGF. E7820 inhibits alpha-2 integrin as well as integrin 3, 5, and ß1 in confluent cultures of HUVEC.
E7820 is a potent inhibitor of endothelial cell proliferation and vascular tube formation in vitro, and it effectively inhibits the growth of human breast and pancreatic cancer xenografts.
Eisai and Quintiles
In October 2009, Eisai entered into a strategic alliance with Eisai to develop six potential oncology products in Eisais R&D pipeline. Under the terms of the agreement, Quintiles oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. The strategic alliance will be structured on a risk-sharing basis, with Quintiles funding, in part, the design and conduct of the clinical studies in exchange for success milestone payments. Other financial terms were not disclosed. The agreement is designed to enable Eisai to extend its oncology program, increasing the number of indications investigated for the six potential products, including eribulin (E7389), E7080, Ontak (denileukin diftitox), E7820, E6201 and E7050. These assets will remain the property of Eisai, with Quintiles having development accountability through the Phase II proof-of-concept stage. Quintiles will collaborate on a Phase Ib/II combo study of E7820 in...See full deal structure in Biomedtracker
Partners: Quintiles Transnational Holdings, Inc.
Pink Sheet FDA's NDA And BLA Approvals
Pink Sheet EMA's PRIME: Helpful But Not A Panacea
Additional information available to subscribers only: